obesity drug news today glp-1 october 23 2025 Use of diabetes and anti-obesity drugs surges nationwide GLP-1 Receptor Agonists Obesity Drugs

Despite this promise, several critical limitations remain: No large-scale, randomized controlled human trials to confirm efficacy, safety, or long-term impact Toxicology and pharmacokinetic data are lacking, especially for chronic use or high-dose regimens Only one stereoisomer (all-L form) has been tested

Is BPC-157 on the WADA banned substances list

Gaudncio FN et al

Some anti-diabetic medications are linked with an increased risk of weight gain or hypoglycemia which may reduce the efficacy of the intended anti-hyperglycemic effects of these therapies

: , , , , ,

Selenium contributes to the normal function of the immune system